Benefits of implantable cardioverter-defibrillators maintained in clinical setting
This article has no abstract so we have provided the first paragraph of the full text.
Patients with left ventricular systolic dysfunction are at risk of ventricular arrhythmias and sudden cardiac death. Meta-analyses of randomized controlled trials (RCTs) have demonstrated that, in these patients, implantable cardioverter-defibrillators (ICDs) reduce mortality by 26% and sudden cardiac death by 57%. Some cardiologists, however, question whether the benefits of ICDs seen in clinical trials extend to clinical practice, where physicians who perform implantation procedures might not have the same level of experience.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
